Clinical Trial Update: A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants [Phase 1]

View source ↗

Summary

A Phase 1 study of Blosozumab (LY2541546) in postmenopausal women with osteoporosis has completed. Results were posted in July 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Blosozumab (LY2541546) (Blosozumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoporosis, Postmenopausal | Phase 1 | Status: COMPLETED | Results posted: 2018-07-16